Aridis Pharmaceuticals Stock Debt To Equity
Aridis Pharmaceuticals fundamentals help investors to digest information that contributes to Aridis Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aridis Pink Sheet. The fundamental analysis module provides a way to measure Aridis Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aridis Pharmaceuticals pink sheet.
Aridis |
Aridis Pharmaceuticals Company Debt To Equity Analysis
Aridis Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Aridis Pharmaceuticals Debt To Equity | (0.18) % |
Most of Aridis Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aridis Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Aridis Pharmaceuticals has a Debt To Equity of -0.1833%. This is 100.34% lower than that of the Biotechnology sector and 100.95% lower than that of the Health Care industry. The debt to equity for all United States stocks is 100.38% higher than that of the company.
Aridis Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aridis Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aridis Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aridis Pharmaceuticals by comparing valuation metrics of similar companies.Aridis Pharmaceuticals is currently under evaluation in debt to equity category among its peers.
Aridis Fundamentals
Return On Asset | -1.08 | ||||
Operating Margin | (9.58) % | ||||
Current Valuation | 12.11 M | ||||
Shares Outstanding | 36.21 M | ||||
Shares Owned By Insiders | 31.53 % | ||||
Shares Owned By Institutions | 11.60 % | ||||
Number Of Shares Shorted | 2 M | ||||
Price To Earning | (1.41) X | ||||
Price To Book | 5.40 X | ||||
Price To Sales | 7.33 X | ||||
Gross Profit | (22.61 M) | ||||
EBITDA | (29.51 M) | ||||
Net Income | (30.37 M) | ||||
Cash And Equivalents | 6.32 M | ||||
Cash Per Share | 0.36 X | ||||
Total Debt | 6.13 M | ||||
Debt To Equity | (0.18) % | ||||
Current Ratio | 0.41 X | ||||
Book Value Per Share | (0.77) X | ||||
Cash Flow From Operations | (29.13 M) | ||||
Short Ratio | 0.22 X | ||||
Earnings Per Share | (1.15) X | ||||
Price To Earnings To Growth | (0.02) X | ||||
Target Price | 10.0 | ||||
Number Of Employees | 37 | ||||
Beta | 0.78 | ||||
Market Capitalization | 13.24 M | ||||
Total Asset | 14.7 M | ||||
Retained Earnings | (195.67 M) | ||||
Working Capital | (25.27 M) | ||||
Current Asset | 27.39 M | ||||
Current Liabilities | 3.06 M | ||||
Z Score | -26.03 | ||||
Net Asset | 14.7 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Aridis Pink Sheet
If you are still planning to invest in Aridis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aridis Pharmaceuticals' history and understand the potential risks before investing.
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |